Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
19 studies found for:    CSF1R
Show Display Options
Rank Status Study
1 Recruiting Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Conditions: Colorectal Cancer;   Pancreatic Cancer;   Metastatic Cancer;   Advanced Cancer
Interventions: Drug: Pexidartinib;   Drug: Durvalumab
2 Recruiting A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Conditions: Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Gastrointestinal Stromal Tumor (GIST);   Ovarian Cancer
Interventions: Drug: PLX3397;   Biological: Pembrolizumab
3 Recruiting Study of DCC-3014 in Patients With Advanced Malignancies
Condition: Advanced Malignant Neoplasm
Intervention: Drug: DCC-3014
4 Recruiting A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: LY3022855;   Drug: Durvalumab;   Drug: Tremelimumab
5 Active, not recruiting A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Condition: Neoplasms
Intervention: Biological: IMC-CS4
6 Recruiting Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Conditions: Pigmented Villonodular Synovitis;   Tenosynovial Giant Cell Tumor
Intervention: Drug: FPA008
7 Recruiting Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
Conditions: Advanced Solid Tumors, Including But Not Limited to Lung Cancer;   Head and Neck Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Renal Cell Carcinoma;   Malignant Glioma
Interventions: Biological: FPA008;   Biological: BMS-936558
8 Recruiting Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis
Conditions: Uterine Neoplasms;   Endometrial Neoplasms
9 Not yet recruiting Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Chiauranib
10 Completed
Has Results
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib
11 Completed To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Condition: Cancer
Interventions: Drug: Sunitinib;   Drug: Sunitinib and Ketoconazol;   Drug: Sunitiinb and Ketoconazol
12 Active, not recruiting ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
Condition: Metastatic Kidney Cancers
Intervention: Diagnostic Test: ELR+CXCL cytokines levels are of sunitinib response
13 Not yet recruiting LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
14 Active, not recruiting PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Conditions: Pigmented Villonodular Synovitis;   Giant Cell Tumors of the Tendon Sheath;   Tenosynovial Giant Cell Tumour
Interventions: Drug: PLX3397 capsule;   Drug: Placebo capsule matching PLX3397 capsule
15 Recruiting Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: BLZ945;   Drug: PDR001
16 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
17 Completed A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
Condition: Metastatic Cancer
Intervention: Drug: ARRY-382, cFMS inhibitor; oral
18 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)
19 Active, not recruiting A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: Paclitaxel;   Drug: RO5509554

Study has passed its completion date and status has not been verified in more than two years.